<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;p style="text-align: left"&gt;DEPARTMENT OF HEALTH AND HUMAN SERVICES&lt;/p&gt;&lt;div style="text-align: left"&gt;Food and Drug Administration&lt;/div&gt;&lt;div style="text-align: left"&gt;[Docket No. FDA&amp;ndash;2010&amp;ndash;N&amp;ndash;0001]&lt;/div&gt;&lt;div style="text-align: left"&gt;Radiological Devices Panel of the Medical Devices Advisory Committee;&lt;/div&gt;&lt;div style="text-align: left"&gt;Notice of Meeting&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;AGENCY: Food and Drug Administration, HHS.&lt;/div&gt;&lt;div style="text-align: left"&gt;ACTION: Notice.&lt;/div&gt;&lt;div style="text-align: left"&gt;This notice announces a forthcoming meeting of a public advisory&lt;/div&gt;&lt;div style="text-align: left"&gt;committee of the Food and Drug Administration (FDA). The meeting will be&lt;/div&gt;&lt;div style="text-align: left"&gt;open to the public.&lt;/div&gt;&lt;div style="text-align: left"&gt;Name of Committee: Radiological Devices Panel of the Medical Devices&lt;/div&gt;&lt;div style="text-align: left"&gt;Advisory Committee.&lt;/div&gt;&lt;div style="text-align: left"&gt;General Function of the Committee: To provide advice and&lt;/div&gt;&lt;div style="text-align: left"&gt;recommendations to the agency on FDA&amp;rsquo;s regulatory issues.&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;b&gt;Date and Time: &lt;/b&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;b&gt;The meeting will be held on September 24, 2010, from &lt;/b&gt;&lt;b&gt;8 a.m. to 6 p.m.&lt;/b&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;b&gt;Location: &lt;/b&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;b&gt;Hilton Washington DC North/Gaithersburg, Salons A, B, C and&lt;/b&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;b&gt;D, 620 Perry Pkwy., Gaithersburg, MD.&lt;/b&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;Contact Person: Shanika Craig, Food and Drug Administration, Center for&lt;/div&gt;&lt;div style="text-align: left"&gt;Devices and Radiological Health, 10903 New Hampshire Ave., Bldg 66, rm.&lt;/div&gt;&lt;div style="text-align: left"&gt;1613, Silver Spring, MD 20993&amp;ndash;0002, 301&amp;ndash;796&amp;ndash;6639, or FDA Advisory&lt;/div&gt;&lt;div style="text-align: left"&gt;Committee Information Line, 1&amp;ndash;800&amp;ndash;741&amp;ndash;8138 (301&amp;ndash;443&amp;ndash;0572 in the&lt;/div&gt;&lt;div style="text-align: left"&gt;Washington, DC area), code 3014512526.&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;Please call the Information Line forup-to-date information on this meeting.&lt;/div&gt;&lt;div style="text-align: left"&gt;A notice in the Federal Register aboutlast minute modifications that impact a previously&lt;/div&gt;&lt;div style="text-align: left"&gt;announced advisory committee meeting cannot always be published quickly enough to provide&lt;/div&gt;&lt;div style="text-align: left"&gt;timely notice. Therefore, you should always check the agency&amp;rsquo;s Web site and&lt;/div&gt;&lt;div style="text-align: left"&gt;call the appropriate advisory committee hot line/phone line to learn about&lt;/div&gt;&lt;div style="text-align: left"&gt;possible modifications before coming to the meeting.&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;strong&gt;Agenda:&lt;/strong&gt; On September 24, 2010, the committee will discuss, make&lt;/div&gt;&lt;div style="text-align: left"&gt;recommendations, and vote on a premarket approval application for the&lt;/div&gt;&lt;div style="text-align: left"&gt;Selenia C Digital Breast Tomosynthesis System, sponsored by Hologic, Inc. The&lt;/div&gt;&lt;div style="text-align: left"&gt;Selenia C Digital Breast Tomosynthesis System is intended for use in the same&lt;/div&gt;&lt;div style="text-align: left"&gt;clinical applications as traditional mammographic systems.&lt;/div&gt;&lt;div style="text-align: left"&gt;FDA intends to make background material available to the public no later&lt;/div&gt;&lt;div style="text-align: left"&gt;than 2 business days before the meeting. If FDA is unable to post the&lt;/div&gt;&lt;div style="text-align: left"&gt;background material on its Web site prior to the meeting, the background&lt;/div&gt;&lt;div style="text-align: left"&gt;material will be made publicly available at the location of the advisory&lt;/div&gt;&lt;div style="text-align: left"&gt;committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web&lt;/div&gt;&lt;div style="text-align: left"&gt;site after the meeting. Background material is available at http://www.fda.gov/&lt;/div&gt;&lt;div style="text-align: left"&gt;AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate&lt;/div&gt;&lt;div style="text-align: left"&gt;advisory committee link.&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;strong&gt;Procedure: &lt;/strong&gt;Interested persons may present data, information, or views,&lt;/div&gt;&lt;div style="text-align: left"&gt;orally or in writing, on issues pending before the committee. Written&lt;/div&gt;&lt;div style="text-align: left"&gt;submissions may be made to the contact person on or before September 16,&lt;/div&gt;&lt;div style="text-align: left"&gt;2010. Oral presentations from the public will be scheduled between&lt;/div&gt;&lt;div style="text-align: left"&gt;approximately 1 p.m. and 2 p.m., immediately following lunch. Those desiring&lt;/div&gt;&lt;div style="text-align: left"&gt;to make formal oral presentations should notify the contact person and submit&lt;/div&gt;&lt;div style="text-align: left"&gt;a brief statement of the general nature of the evidence or arguments they wish&lt;/div&gt;&lt;div style="text-align: left"&gt;to present, the names and addresses of proposed participants, and an&lt;/div&gt;&lt;div style="text-align: left"&gt;indication of the approximate time requested to make their presentation on&lt;/div&gt;&lt;div style="text-align: left"&gt;or before September 9, 2010. Time allotted for each presentation may be&lt;/div&gt;&lt;div style="text-align: left"&gt;limited. If the number of registrants requesting to speak is greater than can&lt;/div&gt;&lt;div style="text-align: left"&gt;be reasonably accommodated during the scheduled open public hearing&lt;/div&gt;&lt;div style="text-align: left"&gt;session, FDA may conduct a lottery to determine the speakers for the&lt;/div&gt;&lt;div style="text-align: left"&gt;scheduled open public hearing session. The contact person will notify&lt;/div&gt;&lt;div style="text-align: left"&gt;interested persons regarding their request to speak by September 10, 2010.&lt;/div&gt;&lt;div style="text-align: left"&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the&lt;/div&gt;&lt;div style="text-align: left"&gt;agency is not responsible for providing access to electrical outlets.&lt;/div&gt;&lt;div style="text-align: left"&gt;FDA welcomes the attendance of the public at its advisory committee&lt;/div&gt;&lt;div style="text-align: left"&gt;meetings and will make every effort to accommodate persons with physical&lt;/div&gt;&lt;div style="text-align: left"&gt;disabilities or special needs. If you require special accommodations due to a&lt;/div&gt;&lt;div style="text-align: left"&gt;disability, please contact AnnMarie Williams, Conference Management Staff,&lt;/div&gt;&lt;div style="text-align: left"&gt;301&amp;ndash;796&amp;ndash;5966, at least 7 days in advance of the meeting.&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="text-align: left"&gt;FDA is committed to the orderly conduct of its advisory committee&lt;/div&gt;&lt;div style="text-align: left"&gt;meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/&lt;/div&gt;&lt;div style="text-align: left"&gt;AboutAdvisoryCommittees/ucm111462.htm for procedures on public conduct&lt;/div&gt;&lt;div style="text-align: left"&gt;during advisory committee meetings.&lt;/div&gt;&lt;div style="text-align: left"&gt;Notice of this meeting is given under the Federal Advisory Committee Act&lt;/div&gt;&lt;div style="text-align: left"&gt;(5 U.S.C. app. 2).&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;em&gt;Dated: July 22, 2010.&lt;/em&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;em&gt;Jill Hartzler Warner,&lt;/em&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&lt;em&gt;Acting Associate Commissioner for Special Medical Programs.&lt;/em&gt;&lt;/div&gt;&lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt;</wcm:element>
</wcm:root>
